Title |
Clostridium difficile Drug Pipeline: Challenges in Discovery and Development of New Agents
|
---|---|
Published in |
Journal of Medicinal Chemistry, March 2015
|
DOI | 10.1021/jm5016846 |
Pubmed ID | |
Authors |
Angie M. Jarrad, Tomislav Karoli, Mark A. T. Blaskovich, Dena Lyras, Matthew A. Cooper |
Abstract |
In the last decade Clostridium difficile has become a bacterial pathogen of global significance. Epidemic strains have spread throughout hospitals, while community acquired infections and other sources ensure a constant inoculation of spores into hospitals. In response to the increasing medical burden, a new C. difficile antibiotic, fidaxomicin, was approved in 2011 for the treatment of C. difficile-associated diarrhea. Rudimentary fecal transplants are also being trialed as effective treatments. Despite these advances, therapies that are more effective against C. difficile spores, less damaging to the resident gastrointestinal microbiome, and that reduce recurrent disease are still desperately needed. However, bringing a new treatment for C. difficile infection to market involves particular challenges. This review covers the current drug discovery pipeline, including both small molecule and biologic therapies, and highlights the challenges associated with in vitro and in vivo models of C. difficile infection for drug screening and lead optimization. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Mexico | 3 | 2% |
United Kingdom | 1 | <1% |
United States | 1 | <1% |
Germany | 1 | <1% |
Unknown | 135 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 26 | 18% |
Researcher | 23 | 16% |
Student > Master | 20 | 14% |
Other | 12 | 9% |
Student > Bachelor | 8 | 6% |
Other | 29 | 21% |
Unknown | 23 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Chemistry | 29 | 21% |
Agricultural and Biological Sciences | 24 | 17% |
Medicine and Dentistry | 20 | 14% |
Biochemistry, Genetics and Molecular Biology | 13 | 9% |
Immunology and Microbiology | 12 | 9% |
Other | 17 | 12% |
Unknown | 26 | 18% |